PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Europital

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

PenThu® Now Compliant with FDA 21 CFR Part 11 and EU Annex 11 - PenThu®, the first Interactive Guidance Management System (IGMS) in the clinical research industry developed by Europital, has reached a new milestone via fulfillment of critical regulatory requirements
PenThu® Now Compliant with FDA 21 CFR Part 11 and EU Annex 11

 

NewswireToday - /newswire/ - Ghent, Oost Vlaanderen, Belgium, 2016/06/20 - PenThu®, the first Interactive Guidance Management System (IGMS) in the clinical research industry developed by Europital, has reached a new milestone via fulfillment of critical regulatory requirements.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The safety of a computer system is reflected by the confidentiality, integrity, and availability of the system. Regulatory requirements define the criteria under which computerized system are considered trustworthy and reliable. The technical and procedural controls of a computer system are required to maintain the accuracy, integrity, and reliability of the data throughout the lifecycle of the records.

Documentary evidence is needed to demonstrate these controls are fit for purpose. Accordingly, the validation of a computer system must address the implementation and maintenance of the controls to enable integrity, including data entered manually and that automatically acquired in addition to the data processing.

Last May 5th, 2016 PenThu®, the Interactive Guidance Management System (IGMS) from Europital, was successfully audited for FDA 21 part 11 and EU Annex 11 compliancy by Ofni Systems, Raleigh, NC (USA).

About Europital

Europital (europital.com) is an international organization dedicated to Medical Management and Scientific Research. We provide our expertise in a flexible end-to-end model tailored for the business needs of our clients in the Pharmaceutical industry and Healthcare sector. Via our niche services and creative solutions, we support private companies and governmental institutes in achieving and maintaining high-quality and efficient work standards.

About PenThu®

PenThu® (penthu.com) is the first Interactive Guidance Management System (IGMS) in the clinical research industry. It is an innovative approach from Europital that drives performance, knowledge and efficiencies via the creation of an interactive environment that provides the kind of transparency needed to share and access information in a way that really maximizes team performance and creates true partnership.

Contact:
Europital BVBA
ICC Building, Van Rysselberghedreef 2
9000 Ghent, Belgium
T: +32 9 331 60 30
F: +32 9 329 55 48
Email: info[.]europital.com

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Europital

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


PenThu® Now Compliant with FDA 21 CFR Part 11 and EU Annex 11

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Patricia Piera - Europital.com 
+32 93316030 info[.]europital.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Europital securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Europital / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)